Open-Label Extension of Other SZ1839 (Iressa) Trials

• Status: Completed
• Trial end date: 2003-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Received treatment in a previous Iressa clinical trial

• Provided Informed Consent to participate in the trial

• 30 days or less since completing the previous Iressa trial.

Exclusion Criteria:

• Radiotherapy completed more than 14 days before starting treatment in this trial

• Incomplete healing from prior surgery

• Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs